Oxcarbazepine (All indications)

ASD (Autism spectrum disorder): Risk

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9964
R35827		 Bjørk (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018 Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) during pregnancy (anytime or not specified) population based cohort propective exposed to other treatment, sick excluded Adjustment: No 0.66 [0.03;13.57] C
excluded (control group) 		0/4   13/76 13 4
ref
S9952
R35815		 Bjørk (Oxcarbazepine) (Controls unexposed, disease free), 2018 Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) during pregnancy (anytime or not specified) population based cohort propective unexposed, disease free excluded Adjustment: No 1.42 [0.07;27.47] C
excluded (control group) 		0/4   6,907/75,497 6,907 4
ref
S9966
R35829		 Bjørk (Oxcarbazepine) (Controls unexposed, sick), 2018 Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: No 1.27 [0.06;25.24] C 0/4   27/272 27 4
ref
Total 1 studies 1.27 [0.06;25.24] 27 4
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bjørk (Oxcarbazepine) (Controls unexposed, sick), 2018Bjørk, 2018 1 1.27[0.06; 25.24]2740%ROB confusion: unclearROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.27[0.06; 25.24]274 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2018 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.27[0.06; 25.24]274 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2018 1 Tags Adjustment   - No  - No 1.27[0.06; 25.24]274 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2018 1 All studiesAll studies 1.27[0.06; 25.24]274 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2018 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9964, 9952

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.42[0.07; 27.47]6,9074 -NABjørk (Oxcarbazepine) (Controls unexposed, disease free), 2018 1 unexposed, sick controlsunexposed, sick controls 1.27[0.06; 25.24]274 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2018 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.66[0.03; 13.57]134 -NABjørk (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018 10.510.01.0